// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























28841 Abstracts

ABOUND.2L+: nab-paclitaxel (nab-P) +/- CC-486 or durvalumab in previously treated patients with advanced non-small cell lung cancer (NSCLC)

D.Morgensztern - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Durvalumab

Comparison of the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) in clinical trials supporting US Food and Drug Administration (FDA) approval of orphan vs. non-orphan drugs

C. MoltoValiente - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Clinical benefit of randomized controlled trials (RCT) supporting US Food and Drug Administration (FDA) conversion from accelerated to full approval

M. BorrellPuy - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Social media and e-mental health

M.Krausz - European Congress of Psychiatry (EPA) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Setting the scene: The evidence for pre-clinical change, projections of the impact of intervention, and implications for public health

T.C.Russ - European Congress of Psychiatry (EPA) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

N/A

Progressive brain changes associated with persistent negative symptoms following a first episode of psychosis

M.Lepage - European Congress of Psychiatry (EPA) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Stress Hormone System and Epigenetics in Depression

V.OKeane - European Congress of Psychiatry (EPA) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

N/A

Association of stress hormone system, epigenetics and imaging

T.Frodl - European Congress of Psychiatry (EPA) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

N/A

Intergenerational transmission of well being–genetic and epigenetic mechanisms

E.Unternaehrer - European Congress of Psychiatry (EPA) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

N/A

Once and again: Intergenerational transmission of parenting

K. TombeauCost - European Congress of Psychiatry (EPA) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

N/A

Early adversity, symptoms of depression and breastfeeding

W.Jonas - European Congress of Psychiatry (EPA) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

Oxytocin

An investigation of the coupling of temperament traits with major depression

W.Sulis - European Congress of Psychiatry (EPA) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

Epimorph

An investigation of the coupling of temperament traits with anxiety

W.Sulis - European Congress of Psychiatry (EPA) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

Epimorph

Integrating the findings from boundary sciences for development of the DSM/ICD classifications

I.Trofimova - European Congress of Psychiatry (EPA) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Acetylcholine

Clinical outcomes of the first 2 years of implementation of the integrated care pathway for concurrent major depressive disorder and alcohol use disorder

A.V.Samokhvalov - European Congress of Psychiatry (EPA) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

N/A

Incidence and predictors of suicide attempts in bipolar I and II disorders: A five-year follow-up

S.Pallaskorpi - European Congress of Psychiatry (EPA) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

N/A

Clinical prediction of suicide attempt in schizophrenia using a machine learning approach

V.De Luc - European Congress of Psychiatry (EPA) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

N/A

The effects of deep-brain magnetic stimulation (DMS) on white matter deficits: New mechanism in major depressive disorder (MDD) treatment

Y.Zhang - European Congress of Psychiatry (EPA) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

N/A

Pharmacogenetic association between glutamatergic genes and sri treatment response in obsessive compulsive disorder

T.Shukla - European Congress of Psychiatry (EPA) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

N/A

The role of micrornas in regulating redox modulation in bipolar disorder

H.Kim - European Congress of Psychiatry (EPA) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

glutathione

Copyright © 2026. QuantiNova All rights reserved